Actual Medicinal Product (AMP) Lamivudine 300mg tablets (A A H Pharmaceuticals Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

Protect from light. No stability data in MCAs available.

Provenance

This recommendation is based on the products Epivir 300mg tablets (ViiV Healthcare UK Ltd) and lamivudine 300mg tablets (Milpharm Aurobindo Pharma - Milpharm Ltd).

Generic
Lamivudine
Formulation
Lamivudine 300mg tablets
  • Lamivudine
    • Lamivudine 300mg tablets

      • Lamivudine 300mg tablets (A A H Pharmaceuticals Ltd)